Madrigal Expands Resmetirom Reach With New Post-Transplant MASH Trial

Madrigal (MDGL) announced an update on their ongoing clinical study.

The Phase 2 study titled “Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate MGL-3196 (Resmetirom) in Patients With MASH Who Have Undergone Liver Transplant for MASH Cirrhosis or Other Etiologies” aims to test resmetirom in post-transplant patients with MASH. It targets patients with moderate to advanced fibrosis, a group with high unmet need and rising healthcare costs.

The study tests resmetirom, an oral drug designed to improve liver fat and inflammation linked to MASH. It compares daily doses of 80 or 100 mg versus placebo to see if the drug can safely manage disease recurrence or new onset MASH after liver transplant.

This is an interventional Phase 2 trial with patients randomly assigned to resmetirom or placebo in parallel groups. The trial is triple-blind, meaning patients, treating doctors, and study investigators do not know who is receiving active drug or placebo, and the main goal is treatment evaluation.

The trial is listed as recruiting, with first submission on 7 Jan 2026, marking its formal entry into the clinical pipeline for this setting. The last update was filed on 29 Apr 2026, showing that the protocol and status were recently reviewed and confirming active operational progress.

For investors, this post-transplant MASH program broadens the potential use of resmetirom beyond earlier-stage disease and could support a premium valuation for Madrigal Pharmaceuticals, Inc. (MDGL) if data are positive, especially as few competitors target this complex niche and transplant-related outcomes are closely watched by payers.

The study remains ongoing and updated, with full details and future changes available on the ClinicalTrials.gov portal.

To learn more about MDGL’s potential, visit the Madrigal drug pipeline page.